Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.

J Peripher Nerv Syst 2018 12 7;23(4):235-240. Epub 2018 Oct 7.

Department of Clinical Neurophysiology, APHP, Pitié-Salpêtrière Hospital, Paris, France.

We aimed to analyse the response to rituximab in a cohort of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients with associated disorders. We conducted a clinical and electrophysiological retrospective monocentric study in 28 CIDP patients. Response to rituximab was defined as (a) a five-point increase in the Medical Research Council sum score or a one-point decrease in the Overall Neuropathy Limitations Scale score, compared to the score at the first rituximab infusion, or (b) the discontinuation of, or reduced need for, the last treatments before rituximab initiation. Twenty-one patients (75%) were responders to rituximab. The median time before response was 6 months (1-10 months). Only two patients needed to be treated again during a median follow-up of 2.0 years (0.75-9 years). Interestingly, the response rate was good in patients with associated autoimmune disease (5/8) and similar to the response rate observed in patients with a haematological disease (16/20) (P = 0.63). A shorter disease duration was associated with a better clinical response to rituximab (odds ratio 0.81, P = 0.025) and the response rate was better (P = 0.05) in common forms (83.3%) than in sensory forms (42.9%). No major adverse events were recorded. Rituximab is efficacious in CIDP patients with haematological or autoimmune disease. It improves clinical response and decreases dependence on first-line treatments.

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jns.12287
Publisher Site
http://dx.doi.org/10.1111/jns.12287DOI Listing
December 2018
11 Reads

Publication Analysis

Top Keywords

cidp patients
12
response rate
12
response rituximab
12
rituximab
8
patients haematological
8
chronic inflammatory
8
patients associated
8
response
8
demyelinating polyradiculoneuropathy
8
inflammatory demyelinating
8
autoimmune disease
8
clinical response
8
patients
7
limitations scale
4
rituximab initiation
4
duration associated
4
75% responders
4
responders rituximab
4
shorter disease
4
disease duration
4

References

(Supplied by CrossRef)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): clinical features, diagnosis, and current treatment strategies
Reynolds J et al.
R I Med J 2016

Mahdi‐Rogers M et al.
2017

Similar Publications